Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Exscientia

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Recipient: Oxford Drug Discovery

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 11, 2021

            Details:

            Exscientia will use its AI-driven technology to generate novel clinical assets targeting this pathway. This will build on years of research by the ARUK-ODDI, which has identified chemical starting points that modulate NLRP3 inflammasome formation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

            Deal Size: $4.2 million Upfront Cash: Undisclosed

            Deal Type: Funding December 10, 2020

            Details:

            Through this partnership, Exscientia will use its Centaur Biologist™ platform to apply domain-specific implementations of knowledge graphs and deep learning algorithms to a diverse wealth of biological data.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Recipient: Hangzhou Zhongmei Huadong Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 09, 2020

            Details:

            Under this collaboration, Exscientia will use its advanced Centaur Chemist AI platform to design new molecules against project specific targets and Huadong will apply its experimental and managerial capabilities to support Exscientia’s AI design in a rapid closed-loop cycle.